Dr Kostas Chiotis' review on "The Role of Amyloid-β and Tau PET in the New Era of Alzheimer Disease Therapies" is now published in the Journal Of Nuclear Medicine. Co-authors include Renaud La Joie and Gil Rabinovici (senior author), and Yingbing Wang, a UCSF radiologist and close collaborator to our group.
This continuing-education article reviews the current clinical validation of Aβ and tau PET imaging in AD, outlines the available evidence for the recently approved anti-Aβ therapies, and examines how PET imaging was operationalized in the trials for these novel therapeutic agents. We explore the potential for translating trial-based imaging protocols into clinical practice—particularly how PET quantification beyond binary visual reads can support nuanced decisions regarding patient eligibility, risk stratification, therapeutic monitoring, and duration of treatment. Finally, we identify key knowledge gaps and unmet needs that must be addressed to facilitate broader clinical adoption of PET imaging, including standardization efforts, accessibility and reimbursement, and evidence-based guidelines for interpretation and use.
